In the present work, the necessity for the use of inhA-15 testing in detecting isoniazid resistance was challenged for the first time. We found that the molecular detection of inhA-15 C to T alterations in the fast detection of isoniazid-resistant tuberculosis (TB) is not necessary and should not be recommended for routine work.
To assess the accuracy of the results of AS-PCR, we utilized the sequence method as the gold standard of molecular parts. Complete conformity (100%) between the results of the sequence method and AS-PCR, indicating the accuracy of the method used, is a molecular perspective.
The majority of the previous investigations has determined the mutation in inhA-15 just in total strains, including the number of the strains susceptible or resistant to isoniazid, and did not specifically determine mutations in katG315 and mutation in inhA-15 separately. In the present study, from the 42 strains resistant to isoniazid, 5 (11.9%) strains had mutations in inhA-15. All 5 strains simultaneously had mutations in inhA-15 and katG315.
It has been previously proven that mutations in the inhA promoter are associated with low-level resistance to isoniazid. Thus, in the discussion of the epidemiology and prevalence of isoniazid, resistance is not very important, while mutations in katG315 are of great significance regarding highlevel resistance to isoniazid. 1 Interestingly, we examined 106 strains resistant to and 62 strains susceptible to isoniazid and obtained results similar to those reported previously by other investigators.
1,3,4 Nonetheless, Wu et al. 5 succeeded in proving inhA-15 mutation in 3 (4.8%) strains susceptible to isoniazid. In the present study, chiming in with the results reported by Wu et al., 5 we detected a case of isoniazid-susceptible phenotype, albeit with mutations in inhA-15.
According to the literature, in phenotypic resistance with no mutations in katG315, resistance can be caused by mutations in inhA-15. The drug-susceptible strain can still be considered sensitive even with harbored mutation at inhA-15 (Wu et al., 2006) . 5 Consequently, phenotypic drug susceptibility testing is more valuable than is the molecular testing of inhA-15.
Given the findings of the current study and those reported by Wu et al. 5 apropos isoniazid-susceptible strains harboring mutation in inhA-15, we conclude that inhA-15 testing cannot provide valuable results in comparison with the fast and highly valuable test of katG315.
Clinical practice requires expedited detection, increased accuracy, decreased costs, and reduced number of samples per day and, thus, reduced workload. Accordingly, it is of scientific and strategic significance that unnecessary work such as that in the evaluation of molecular resistance to isoniazid be avoided in routine practice.
The detection of mutations in KatG315 with or without the results of mutations in inhA-15 is sufficient for the prediction of resistance to isoniazid. Mutations in inhA-15 cannot be valuable as a complementary test for the rapid detection of resistance to isoniazid in the clinical isolates of TB in routine work.
